



Circular 17/19

Re: Introduction of Idebenone (Raxone) and Ataluren (Translarna)

Dear Pharmacist,

With effect from 1st May 2019 Raxone 150mg tablets, Translarna 125mg granules for oral suspension, Translarna 250mg granules for oral suspension and Translarna 1,000mg granules for oral suspension are newly approved under the High Tech Arrangement.

Raxone 150mg film coated tablets are indicated for the treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy.

Translarna granules for oral suspension are indicated for the treatment of Duchenne Muscular Dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older.

Approved prescribers have been requested to input prescriptions for these products directly onto the High Tech Hub to ensure that the patient meets the reimbursement criteria approved by the HSE. It is important to note that all High Tech prescription forms generated on the hub are prefaced by 'HTH'.

High Tech prescriptions which are not hub generated for Raxone or Translarna will not be eligible for reimbursement by the HSE and will be deemed a private transaction. The suppliers of these products have been informed that the HSE will only reimburse for orders that are generated on the High Tech Hub and the HSE will not approve an order in the absence of an approved prescriber generating the prescription on our Hub infrastructure.

Should you have any queries relating to ordering, please contact the High Tech Co-ordination Unit at PCRS.HiTech@hse.ie or alternatively on 01 8647135. The team are available Monday to Friday, from 08:00 to 19:00.

The codes for the new additions to the list of High Tech reimbursable items are as follows:

Proprietary name index	Non-Proprietary name	Code
Raxone 150mg film coated tablets	Idebenone	88947
Translarna granules for oral susp. 125mg sachets	Ataluren	88946
Translarna granules for oral susp. 250mg sachets	Ataluren	88948
Translarna granules for oral susp. 1000mg sachets	Ataluren	88949

Yours faithfully,

Anne Marie Hoey
Primary Care Reimbursement and Eligibility